Display Settings:

Format

Send to:

Choose Destination
    Int J Oncol. 2011 Oct;39(4):949-53. doi: 10.3892/ijo.2011.1110. Epub 2011 Jul 1.

    Protein-based nanotechnology: antibody conjugated with photosensitizer in targeted anticancer photoimmunotherapy.

    Source

    Urology Research Center, Department of Urology, The University of Toledo - Health Science Campus, 3000 Arlington Ave., Toledo, OH 43614, USA. jerzy.jankun@utoledo.edu

    Abstract

    Photodynamic therapy (PDT) is a minimally invasive cancer therapy that depends on the buildup of a photosensitizing drug within targeted tissue. The photosensitizer is subsequently activated by light of a specific wavelength, resulting in destruction of the targeted tissue by free radicals or singlet oxygen. Successful treatment requires delivery of critical amounts of drug into the cancerous tissue. This frequently demands high doses of the drug in the circulatory system that could lead to side effects in normal daylight due to accumulation of photodrug in normal tissue. To reduce drug load we explored the possibility of targeting cancer with antibody conjugated with photosensitizer. As a model we used LnCAP human prostate cancer cells targeted by antibody (against prostate-specific membrane antigen) which was conjugated with hematoporphyrin (HP). Our results show clearly that mAb/HP conjugates can deliver HP to the tumor cells which would result in considerably less HP in the circulation and, therefore, lower the delivery of HP to normal tissue, resulting in fewer side effects.

    PMID:
    21725592
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Spandidos Publications

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk